441 related articles for article (PubMed ID: 29957886)
1. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
Feng WH; Bi Y; Li P; Yin TT; Gao CX; Shen SM; Gao LJ; Yang DH; Zhu DL
J Diabetes Investig; 2019 Mar; 10(2):399-407. PubMed ID: 29957886
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Feng W; Gao C; Bi Y; Wu M; Li P; Shen S; Chen W; Yin T; Zhu D
J Diabetes; 2017 Aug; 9(8):800-809. PubMed ID: 28332301
[TBL] [Abstract][Full Text] [Related]
3. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
[TBL] [Abstract][Full Text] [Related]
6. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
[TBL] [Abstract][Full Text] [Related]
7. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.
Perna S; Guido D; Bologna C; Solerte SB; Guerriero F; Isu A; Rondanelli M
Aging Clin Exp Res; 2016 Dec; 28(6):1251-1257. PubMed ID: 26749118
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
Tian F; Zheng Z; Zhang D; He S; Shen J
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
[TBL] [Abstract][Full Text] [Related]
10. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Zhang LY; Qu XN; Sun ZY; Zhang Y
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):674-680. PubMed ID: 32113823
[TBL] [Abstract][Full Text] [Related]
11. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.
Shibuya T; Fushimi N; Kawai M; Yoshida Y; Hachiya H; Ito S; Kawai H; Ohashi N; Mori A
Diabetes Obes Metab; 2018 Feb; 20(2):438-442. PubMed ID: 28719078
[TBL] [Abstract][Full Text] [Related]
12. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
[TBL] [Abstract][Full Text] [Related]
13. Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study.
Nakaguchi H; Kondo Y; Kyohara M; Konishi H; Oiwa K; Terauchi Y
J Diabetes Investig; 2020 Nov; 11(6):1542-1550. PubMed ID: 32279451
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
Keskin L; Yaprak B
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6813-6820. PubMed ID: 36196729
[TBL] [Abstract][Full Text] [Related]
15. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
[TBL] [Abstract][Full Text] [Related]
16. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
Pareek A; Chandurkar N; Zawar S; Agrawal N
Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide in Children and Adolescents with Type 2 Diabetes.
Tamborlane WV; Barrientos-Pérez M; Fainberg U; Frimer-Larsen H; Hafez M; Hale PM; Jalaludin MY; Kovarenko M; Libman I; Lynch JL; Rao P; Shehadeh N; Turan S; Weghuber D; Barrett T;
N Engl J Med; 2019 Aug; 381(7):637-646. PubMed ID: 31034184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
